Organon to present new research at ISPOR 2026

Organon (OGN) will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Key data from Organon’s portfolio to be presented include: An examination of the cost-effectiveness and budget impact of Nexplanon 68 mg Radiopaque in Brazil, including analyses that incorporate real-world utilization data and private payer perspectives. A budget impact analysis of Vtama cream, 1%, for the treatment of atopic dermatitis in adult and pediatric patients from a U.S. Medicaid plan perspective. Analyses related to Poherdy 420 mg/14 mL injection for intravenous use in certain HER2-positive breast cancer, as well as a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization. An exploration of real-world referral patterns and healthcare utilization among patients with headache disorders in the United Kingdom.